Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,982 | -23,092 | -5,512 | -25,126 | -16,048 |
| Depreciation Amortization | 43 | N/A | N/A | 5 | 4 |
| Accounts receivable | 12 | N/A | N/A | N/A | N/A |
| Other Working Capital | 51 | -516 | N/A | 5,291 | 5,377 |
| Other Operating Activity | 18,477 | 16,100 | 2,032 | 9,193 | 2,128 |
| Operating Cash Flow | $-10,399 | $-7,508 | $-3,480 | $-10,637 | $-8,539 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | -2,561 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-2,561 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 5,227 | 5,452 | 5,000 | 7,079 | 2,941 |
| Debt Repayment | -394 | -394 | -320 | -8,575 | -4,800 |
| Common Stock Issued | 9,468 | 3,255 | 3,255 | 5,911 | 5,911 |
| Other Financing Activity | 4,400 | 662 | -350 | 3,070 | 1,538 |
| Financing Cash Flow | $18,701 | $8,975 | $7,585 | $7,485 | $5,590 |
| Beginning Cash Position | 1,443 | 1,443 | 1,443 | 4,595 | 4,595 |
| End Cash Position | 7,184 | 2,910 | 5,548 | 1,443 | 1,646 |
| Net Cash Flow | $5,741 | $1,467 | $4,105 | $-3,152 | $-2,949 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,399 | -7,508 | -3,480 | -10,637 | -8,539 |
| Free Cash Flow | -10,399 | -7,508 | -3,480 | -10,637 | -8,539 |